These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34529150)

  • 61. Health technology assessment and economic evaluation: arguments for a national approach.
    Vale L
    Value Health; 2010; 13(6):859-61. PubMed ID: 20701729
    [No Abstract]   [Full Text] [Related]  

  • 62. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 63. To HTA or Not to HTA: Identifying the Factors Influencing the Rapid Review Outcome in Ireland.
    Murphy A; Redmond S
    Value Health; 2019 Apr; 22(4):385-390. PubMed ID: 30975388
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pitfalls in reimbursement decisions for oncology drugs in South Korea: need for addressing the ethical dimensions in technology assessment.
    Cho E; Park EC; Kang MS
    Asian Pac J Cancer Prev; 2013; 14(6):3785-92. PubMed ID: 23886183
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Digital Health Reimbursement Strategies of 8 European Countries and Israel: Scoping Review and Policy Mapping.
    van Kessel R; Srivastava D; Kyriopoulos I; Monti G; Novillo-Ortiz D; Milman R; Zhang-Czabanowski WW; Nasi G; Stern AD; Wharton G; Mossialos E
    JMIR Mhealth Uhealth; 2023 Sep; 11():e49003. PubMed ID: 37773610
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Access and reimbursement pathways for digital health solutions and
    Mantovani A; Leopaldi C; Nighswander CM; Di Bidino R
    Front Med Technol; 2023; 5():1101476. PubMed ID: 36891483
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Assessing the benefits of digital health solutions in the societal reimbursement context].
    Albrecht UV; Kuhn B; Land J; Amelung VE; von Jan U
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Mar; 61(3):340-348. PubMed ID: 29368121
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Problems and Barriers Related to the Use of Digital Health Applications: Scoping Review.
    Giebel GD; Speckemeier C; Abels C; Plescher F; Börchers K; Wasem J; Blase N; Neusser S
    J Med Internet Res; 2023 May; 25():e43808. PubMed ID: 37171838
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Health technology assessment and policy from the economic perspective.
    Rutten F
    Int J Technol Assess Health Care; 2004; 20(1):67-70. PubMed ID: 15176179
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Implementation Road Map of Health Technology Assessment in Middle-Income Countries: The Case of Jordan.
    Almomani E; Alabbadi I; Fasseeh A; Al-Qutob R; Al-Sharu E; Hayek N; Tarawneh MR; Kaló Z
    Value Health Reg Issues; 2021 Sep; 25():126-134. PubMed ID: 34015521
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Estimating the value of implementing reimbursement decisions: What can payers and manufacturers learn from economics?
    Dixon S
    Healthc Manage Forum; 2019 Nov; 32(6):303-306. PubMed ID: 31248283
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Drug Policy in Estonia.
    Mägi K; Lepaste M; Szkultecka-Dębek M
    Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
    Neumann D; Jabłecka A
    Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Pharmacoeconomic studies - usability for reimbursement decisions].
    Dietrich ES; Nakashima T; Ahrens S
    Dtsch Med Wochenschr; 2010 Feb; 135(8):333-8. PubMed ID: 20165996
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan.
    Kamae I
    Pharmacoeconomics; 2010; 28(10):831-8. PubMed ID: 20831290
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evidence of How Physicians and Their Patients Adopt mHealth Apps in Germany: Exploratory Qualitative Study.
    Schroeder T; Haug M; Georgiou A; Seaman K; Gewald H
    JMIR Mhealth Uhealth; 2024 Jan; 12():e48345. PubMed ID: 38231550
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Assessing the capacity of Ghana to introduce health technology assessment: a systematic review of economic evaluations conducted in Ghana.
    Addo R; Goodall S; Hall J; Haas M
    Int J Technol Assess Health Care; 2020 Oct; 36(5):500-507. PubMed ID: 32981532
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment.
    Zemplényi A; Tachkov K; Balkanyi L; Németh B; Petykó ZI; Petrova G; Czech M; Dawoud D; Goettsch W; Gutierrez Ibarluzea I; Hren R; Knies S; Lorenzovici L; Maravic Z; Piniazhko O; Savova A; Manova M; Tesar T; Zerovnik S; Kaló Z
    Front Public Health; 2023; 11():1088121. PubMed ID: 37181704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.